Caplin Point Laboratories Limited (CAPLIPOINT) AI Stock Analysis

• Market Cap: ₹126.38B
• Dividend Yield: 0.31%
• Average Volume (3M): 3.75K
• Price to Earnings (P/E): 21.3
• Beta (1Y): 1.28
• Revenue Growth: 11.41%
• EPS Growth: 19.22%
• Country: IN
• Employees: 3,406
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 21.80
• Shares Outstanding: 76,011,696
• 10 Day Avg. Volume: 2,866
• 30 Day Avg. Volume: 3,752
• PEG Ratio: 1.63
• Price to Book (P/B): 5.30
• Price to Sales (P/S): 7.78
• P/FCF Ratio: 62.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 100.3
• Revenue Forecast (FY): ₹26.53B

• Rating: 69 Neutral
• Price Target: ₹1,821.00 ▼(-1.35% Downside)
• Action: Downgraded Date: 09/27/25
• Date: Action: Downgraded 09/27/25

Caplin Point Laboratories' strong financial performance is the primary driver of its stock score, reflecting robust revenue growth and solid profitability. However, technical indicators suggest a bearish trend, and the valuation appears moderately high, which tempers the overall score.

Positive Factors

Strong revenue & margins

Sustained top-line expansion coupled with robust gross and operating margins indicates the company can convert sales into profitable operations. Durable margin strength supports reinvestment, R&D or capacity expansion and provides resilience to input cost cycles over the next few quarters.

Negative Factors

Tender-driven revenue exposure

Significant reliance on tender and contract procurement exposes revenue and pricing to periodic competitive pressure and award cycles. This structural exposure can compress margins and create lumpiness in volumes, complicating forecastability and long-term margin stability.

Caplin Point Laboratories Limited Business Overview & Revenue Model

Company Description

Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsu...

Read more

Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsu...

How the Company Makes Money

Caplin Point makes money primarily by selling generic pharmaceutical products, with revenue generated from (1) international sales of finished-dosage formulations to distributors, hospitals, pharmacies, and institutional buyers in its key overseas...

Read more

Caplin Point makes money primarily by selling generic pharmaceutical products, with revenue generated from (1) international sales of finished-dosage formulations to distributors, hospitals, pharmacies, and institutional buyers in its key overseas...

Caplin Point Laboratories Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	20.42B	19.40B	16.96B	14.68B	12.71B	10.62B
Gross Profit	11.43B	11.38B	9.40B	7.89B	6.99B	5.82B
EBITDA	7.29B	6.49B	5.51B	4.40B	3.94B	3.28B
Net Income	5.89B	5.36B	4.57B	3.76B	3.00B	2.42B
Balance Sheet
Total Assets	35.04B	32.09B	26.98B	21.91B	17.36B	13.64B
Cash, Cash Equivalents and Short-Term Investments	10.17B	9.03B	7.88B	6.50B	5.13B	4.46B
Total Debt	85.00M	50.20M	19.70M	54.80M	21.30M	183.92M
Total Liabilities	3.05B	3.22B	3.51B	2.84B	2.26B	1.60B
Stockholders Equity	31.59B	28.50B	23.16B	18.80B	14.84B	11.86B
Cash Flow
Free Cash Flow	1.60B	2.41B	1.73B	779.00M	2.46B	1.95B
Operating Cash Flow	2.54B	4.32B	3.18B	2.72B	3.37B	2.66B
Investing Cash Flow	-2.99B	-3.35B	-3.20B	-2.18B	-3.77B	-294.40M
Financing Cash Flow	-460.10M	-383.20M	-380.70M	-281.70M	-407.10M	-239.78M

Caplin Point Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1845.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAPLIPOINT, the sentiment is Neutral. The current price of 1845.95 is above the 20-day moving average (MA) of 1615.85, above the 50-day MA of 1689.76, and below the 200-day MA of 1935.37, indicating a neutral trend. The MACD of -22.35 indicates Negative momentum. The RSI at 54.33 is Neutral, neither overbought nor oversold. The STOCH value of 86.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:CAPLIPOINT.

Caplin Point Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATCOPHARM	76 Outperform	₹201.40B	26.69	―	0.57%	-3.79%	-20.88%
GRANULES	73 Outperform	₹154.16B	24.17	―	0.24%	8.14%	5.18%
CAPLIPOINT	69 Neutral	₹126.38B	21.31	―	0.31%	11.41%	19.22%
NEULANDLAB	60 Neutral	₹189.03B	119.97	―	0.08%	0.34%	-14.13%
APLLTD	57 Neutral	₹141.54B	31.27	―	1.28%	11.42%	-1.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%